# reload+after+2024-01-22 17:46:18.827857
address1§One Broadway
address2§14th Floor
city§Cambridge
state§MA
zip§02142
country§United States
phone§857 357 7000
website§https://www.nuvalent.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§89
companyOfficers§[{'maxAge': 1, 'name': 'Dr. James R. Porter Ph.D.', 'age': 47, 'title': 'CEO, President & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 998020, 'exercisedValue': 0, 'unexercisedValue': 21895162}, {'maxAge': 1, 'name': 'Prof. Matthew D. Shair Ph.D.', 'age': 54, 'title': 'Founder, Head of Scientific Advisory Board & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 235000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alex  Balcom CPA, M.B.A.', 'age': 38, 'title': 'CFO & Treasurer', 'yearBorn': 1985, 'fiscalYear': 2022, 'totalPay': 654216, 'exercisedValue': 0, 'unexercisedValue': 4436413}, {'maxAge': 1, 'name': 'Dr. Christopher D. Turner M.D.', 'age': 54, 'title': 'Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 714256, 'exercisedValue': 0, 'unexercisedValue': 3111506}, {'maxAge': 1, 'name': 'Dr. Benjamin  Lane', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Deborah Ann Miller J.D., Ph.D.', 'age': 47, 'title': 'Chief Legal Officer & Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 595959, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Metivier', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Darlene  Noci', 'age': 46, 'title': 'Chief Development Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Henry  Pelish Ph.D.', 'title': 'Senior Vice President of Drug Discovery', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Soglia Ph.D.', 'title': 'Senior Vice President of Translational Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.382
currency§USD
dateShortInterest§1702598400
forwardEps§-2.91
exchange§NMS
quoteType§EQUITY
shortName§Nuvalent, Inc.
longName§Nuvalent, Inc.
firstTradeDateEpochUtc§1627565400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6d3cb61d-60b2-3511-a49b-f3aa9d7c84d1
gmtOffSetMilliseconds§-18000000
targetHighPrice§100.0
targetLowPrice§68.0
targetMeanPrice§79.0
targetMedianPrice§72.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§14.2
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
